CTOs on the Move

TwelveStone Health Partners

www.12stonehealth.com

 
TwelveStone is focused on the medication needs of patients with complex and chronic conditions. For more than 35 years, TwelveStone has been dedicated to finding new ways to deliver care designed around the patient. Chronic conditions include Multiple Sclerosis, Cystic Fibrosis, Hemophilia, Crohn`s Disease, Growth Deficiency, HIV, Leukemia, and many others. For patients, we provide access to the most advanced medications, along with the personal and financial support patients need to live with chronic conditions. For providers, we simplify treatment for complex conditions by eliminating the administrative and clinical burdens placed on your practice when patients need innovative specialty medication. ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.12stonehealth.com
  • 352 W Northfield Boulevard Suite 3
    Murfreesboro, TN USA 37129
  • Phone: 844.893.0012

Executives

Name Title Contact Details
Jared Burgess
Director of Information Technology and Infrastructure Profile
Chris Porter
Director of Information Technology and Infrastructure Profile

Similar Companies

ValSource

ValSource, LLC is a Downingtown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fralex Therapeutics

Fralex Therapeutics is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vanta Bioscience

Vanta Bioscience is a West Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ryan TrueHealth

Ryan TrueHealth is a Wilton, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.